HR 795 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Pregnancy Is Not an Illness Act of 2025
To prohibit the Department of Health and Human Services from treating pregnancy as an illness for purposes of approving abortion drugs.
Summary
The bill prohibits the Department of Health and Human Services and the Food and Drug Administration from treating pregnancy as an illness when approving abortion medications or establishing safety requirements for them. It nullifies all existing approvals of abortion drugs that relied on treating pregnancy as an illness, including the current approval of mifepristone. The effect would be to eliminate the regulatory basis for abortion medications that were approved based on treating pregnancy as a medical condition.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
11 cosponsors
- Rep. Babin, Brian [R-TX-36] (R-TX)
- Rep. Brecheen, Josh [R-OK-2] (R-OK)
- Rep. Green, Mark E. [R-TN-7] (R-TN)
- Rep. Harris, Andy [R-MD-1] (R-MD)
- Rep. Harris, Mark [R-NC-8] (R-NC)
- Rep. McGuire, John J. [R-VA-5] (R-VA)
- Rep. Moore, Riley [R-WV-2] (R-WV)
- Rep. Ogles, Andrew [R-TN-5] (R-TN)
- Rep. Tenney, Claudia [R-NY-24] (R-NY)
- Rep. Weber, Randy K. Sr. [R-TX-14] (R-TX)
- Rep. Webster, Daniel [R-FL-11] (R-FL)
Money behind the sponsor
Top reported contributors to Mary E. Miller’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- NULL $22,349
- SAULSBURY INDUSTRIES $13,200
- THOMPSON THRIFT DEVELOPMENT $11,600
- KASPAR LAW COMPANY $6,600
- INDECK ENERGY SERVICES $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Mary E. Miller → · Outside spending →
Actions (2)
- Jan 28, 2025 Referred to the House Committee on Energy and Commerce. · house
- Jan 28, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
January 28, 2025
Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of West Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. Tenney, Mr. Harris of Maryland, and Mr. Weber of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To prohibit the Department of Health and Human Services from treating pregnancy as an illness for purposes of approving abortion drugs.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Pregnancy Is Not an Illness Act of 2025”.
SEC. 2. PROHIBITION AGAINST TREATING PREGNANCY AS ILLNESS FOR PURPOSES OF APPROVING ABORTION DRUGS.
(a) Prohibition.—The Department of Health and Human Services, including the Food and Drug Administration, shall not treat pregnancy as an illness for purposes of—
(1) approving any abortion drug under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or
(2) imposing or maintaining any risk evaluation and mitigation strategy for an abortion drug under section 505-1 of such Act (21 U.S.C. 355-1).
(b) Nullification of Approvals in Effect.—
(1) In general.—Any prohibited approval of an abortion drug is hereby nullified.
(2) Prohibited approval defined.—In this subsection, the term “prohibited approval of an abortion drug”—
(A) means any approval of an abortion drug under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) that relied in whole or in part on the treatment of pregnancy as illness; and
(B) includes the approval of mifepristone in effect under such section 505 on the day before the date of enactment of this Act. <all>
Comments